Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising. 

• The company’s Cameron field exploration program was designed to refine previously identified REE geochemical anomalies and improve the definition of potential bedrock source areas.
• Powermax collected 250 samples, including rock-chip, soil and stream-sediment samples, with laboratory results now pending.
• Cameron adds another exploration opportunity to Powermax’s broader portfolio of rare-earth projects in Canada and the United States.
• Growing demand for rare earth elements, combined with China’s dominant position in processing and continuing export restrictions, is increasing the strategic importance of alternative supply.
• The next important catalyst for Powermax will be the release and interpretation of the 2026 Cameron analytical results, while the project remains at an early exploration stage.

Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF), a Canadian mineral exploration company, has completed its 2026 field exploration program at the Cameron Rare Earth Element Project in British Columbia, moving the project into an important analytical phase as investors continue to focus on the global shortage of non-Chinese critical-mineral supply.

The July-August campaign produced a substantial new dataset. Powermax collected 250 samples across priority areas of the approximately 2,984-hectare Cameron project, including 50 rock-chip samples, 50 soil samples and 150 stream-sediment samples. All samples have been submitted to AGAT Laboratories in Calgary for analysis. The company said results will be released after they are received and subjected to its quality-control and quality-assurance review (https://ibn.fm/1deMT). 

Previous exploration identified REE geochemical anomalies at Cameron. Those results, together with mapped pegmatite occurrences and historical mineral occurrences helped determine where Powermax concentrated its 2026 work. The latest campaign was designed to improve the geological picture and identify potential bedrock source areas that could warrant additional investigation.

Field teams documented a range of rock types during the campaign, including gneissic and granodioritic rocks, quartzite, pegmatitic material and quartz-veined or contact-zone material. Quartz, feldspar, biotite and muscovite were commonly recorded, along with localized oxidation and iron staining.

Those observations are useful for geological interpretation, but they should not be confused with assay results. Field descriptions alone cannot establish REE grades or economic significance. The same caution applies to handheld radiometric readings taken at selected locations. The measurements were used as field-screening information to assist mapping and sample selection rather than as direct determinations of REE concentrations.

The company’s earlier work provides the context for the new campaign. Powermax reported REE anomalies from soil and stream-sediment sampling earlier in 2026, leading to additional investigation of priority areas. The new samples now provide an opportunity to test those areas with a broader and more systematic dataset.

The next step is therefore straightforward but potentially important: laboratory assays will determine whether the geological observations and previous anomalies are supported by meaningful concentrations of rare earth elements.

That exploration work is taking place against a backdrop of increasing concern over the structure of the global rare-earth supply chain. Rare earth elements are essential inputs for permanent magnets used in numerous advanced technologies. The most commercially significant magnetic REEs include neodymium and praseodymium, with dysprosium and terbium also important where high-temperature performance is required.

Demand is expected to rise sharply over the coming decade. McKinsey has estimated that demand for magnetic rare earths could increase from approximately 59,000 tonnes in 2022 to 176,000 tonnes by 2035. The same analysis indicated that the currently announced project pipeline could leave the market with a potential supply shortfall.

That imbalance has consequences well beyond the mining industry. China remains the dominant participant in the rare-earth supply chain, particularly in processing. Beijing has also imposed export controls affecting several critical rare-earth materials, highlighting the vulnerability of manufacturers that depend on concentrated overseas supply chains.

For the United States and its allies, developing alternative sources is increasingly viewed as a strategic requirement rather than simply a commodity-market opportunity. The U.S. government has consequently been directing substantial funding toward domestic critical-mineral and magnet supply chains. Canadian projects can potentially benefit from this policy environment because of the close integration between the two countries’ mineral and manufacturing industries.

Cameron is not Powermax’s only exposure to the rare-earth opportunity. The company also has interests in the Atikokan, Hopkins and Pinard REE properties in Ontario, while its Ogden Bear Lodge Project in Wyoming is held 100%. That geographic diversification gives investors exposure to exploration opportunities on both sides of the Canada-U.S. border.

Ogden Bear Lodge is particularly interesting from a strategic perspective because it is located in Crook County, Wyoming, adjacent to the Bear Lodge Critical Rare Earth Project being advanced by Rare Element Resources.

For more information, visit the company’s website at www.PowermaxMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to PWMXF are available in the company’s newsroom at https://ibn.fm/PWMXF

Investor conferences can take a lot of different forms. Some lean heavily toward networking, while others focus primarily on company presentations and scheduled investor meetings.

The Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference falls into the latter category. Organized by an investment bank, the two-day event is designed to bring emerging and under-covered companies together with investors actively looking for opportunities in the small- and mid-cap markets.

Moody Capital Solutions is an investment bank with a roughly 40-year history and offices in Alpharetta, Georgia, and at 230 Park Avenue in New York. A FINRA and SIPC member, the firm provides capital raising, M&A and advisory services to public and private companies, with a focus that includes life sciences, technology and healthcare. In February 2025, Moody Capital consolidated its Capitalyst division into the parent firm, expanding its investment banking capabilities.

That background helps explain the structure of the conference. Rather than building the agenda around broad industry discussions, much of the programming focuses on issues that emerging companies and their investors are dealing with now: raising capital, accessing the public markets, maintaining a listing and connecting directly with potential investors.

Chairman and CEO Richard H. Kreger has framed the 2026 conference around two areas experiencing particularly strong activity. He noted that “artificial intelligence has lit a fire for quickly scaling emerging growth companies,” while life sciences is seeing “unprecedented growth amid a spike of FDA approvals, corporate buyouts and deregulation.”

Those themes form the conference’s two primary tracks, which will run concurrently across both days.

The life sciences track includes biotechnology, medical devices, pharmaceuticals, healthcare technology and diagnostics. Confirmed presenters include American Gene Technologies, BiovaXys, Citius Pharmaceuticals, CytoSorbents, GT Biopharma, ProMIS Neurosciences, Soligenix and NurExone Biologic.

The disruptive growth track focuses on technology, energy and infrastructure. Presenting companies include AIB Data Centers, Axe Compute, Bit Digital, Century Lithium, Eco Wave Power, NeoVolta, Ocean Power Technologies, Interlink Electronics, Intrusion Inc., AmpliTech, U.S. Gold Corp and GPO Plus, among others.

More than 50 companies are scheduled to present in total, with presentations delivered in person by members of their executive teams. NeoVolta’s Wednesday, September 9 presentation, for example, is scheduled for 4:05 p.m. ET and will be led by CEO Ardes Johnson.

Alongside the two primary tracks, the conference will also feature a dedicated Mr. Crowd(R) crowdfunding track for private companies raising capital.

That gives investors another category of companies to explore during the event. Most small-cap investor conferences are centered on publicly traded companies. Here, attendees will also have access to private companies that may be at an earlier point in the capital-raising process.

For family offices and accredited individual investors, both of which are part of the conference’s intended audience, having public and private opportunities available at the same event broadens the range of companies they can evaluate.

Presentations are only one part of the two-day schedule. The announced agenda also includes:

• One-on-one investor meetings scheduled through the conference platform and held throughout both days
• Executive fireside chats offering longer, moderated conversations with management teams
• Capital markets outlook panels focused on the current financing environment
• Panels on going public and remaining listed, including discussions around uplisting, compliance and maintaining a public listing
• Networking receptions bringing company executives together with institutional investors, family offices and other attendees

The mix of programming reflects the two groups the conference is designed to bring together. Company executives have access to discussions about financing and navigating the public markets, while investors have dedicated time for presentations, one-on-one meetings and direct conversations with management.

Investor registration and one-on-one scheduling are handled through the MeetMax platform. Registered investors can attend company presentations and request individual meetings with participating management teams.

In late August, Moody Capital engaged IBN (InvestorBrandNetwork) as the conference’s official media partner.

IBN will support the event through article syndication, press release distribution and social media amplification across a network that includes more than 70 branded properties, over 2 million social media followers and more than 5,000 syndication partners.

For presenting companies, that creates opportunities for conference-related announcements and coverage to reach audiences beyond those attending in New York. It also gives investors another way to follow company news and conference developments before, during and after the event.

The format is fairly straightforward: two days, two primary tracks, more than 50 presenting companies, a private-company crowdfunding track and dedicated time for one-on-one investor meetings.

The focus throughout is direct access. For emerging companies, that means getting in front of investors who may not otherwise encounter their stories through traditional research coverage. For investors, it means being able to hear directly from management, ask questions and compare a large number of opportunities in a relatively short period of time.

With both biotech and AI-related infrastructure attracting significant investor attention in 2026, the timing gives those conversations additional relevance.

Getting the most out of the conference will ultimately come down to preparation: identifying the companies worth seeing, requesting the right meetings and deciding which presentations warrant a closer look after everyone leaves the Westin.

To register to attend the 2026 Disruptive Growth & Life Sciences Conference, visit: https://moodycapital.com/conference/

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) and may include paid advertising.

• Investors in biotechnology often look for companies with a clear path toward clinical development, where regulatory preparation, manufacturing readiness and access to capital can help reduce execution risk.
• Onco-Innovations Ltd. is advancing ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to target DNA repair pathways involved in cancer survival and treatment resistance.
• The company has strengthened its clinical foundation through manufacturing milestones, IND-enabling activities, strategic partnerships and a recent funding arrangement designed to support continued advancement of its oncology pipeline.

For biotechnology investors, a clear path to the clinic can be one of the most important indicators of a company’s development potential. In oncology, where programs often face significant scientific, regulatory and financial hurdles, companies that demonstrate measurable progress across manufacturing, preclinical testing and operational execution may be better positioned to advance promising therapies.

Beyond scientific validation, access to capital is another critical component of clinical development. Drug candidates require substantial resources to move from discovery through regulatory milestones and into human studies, making strategic financing an important factor in sustaining momentum.

This combination of scientific progress and operational execution is particularly important in oncology, where therapies addressing difficult-to-treat cancers and treatment resistance can represent significant opportunities if successfully developed.

One company working to advance this transition is Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H), a preclinical-stage precision oncology company focused on developing therapies targeting DNA Damage Response (“DDR”) pathways.

The company’s lead candidate, ONC010, is a nanoparticle-encapsulated Polynucleotide Kinase Phosphatase (“PNKP”) inhibitor designed to interfere with DNA repair mechanisms that cancer cells rely on for survival and resistance.

Building the Foundation for Clinical Development

Onco-Innovations has recently achieved several milestones designed to support the continued development of ONC010. The company completed a successful 300-gram active pharmaceutical ingredient (“API”) scale-up, achieving approximately 99.3% purity with residual solvents below the limits of detection of the analytical methods employed, representing an important step toward establishing scalable manufacturing capabilities.

The company has also expanded its manufacturing and formulation capabilities through strategic collaborations, including its partnership with Nanosoft Polymers to support the development, optimization and scaling of the polymer manufacturing process used for ONC010.

Additional development activities include metabolism studies, analytical characterization, exclusive licensing agreements supporting intellectual property protection, and other IND-enabling studies designed to advance the program toward regulatory submission.

Capital Formation Supports Continued Advancement

Alongside these scientific and manufacturing milestones, Onco-Innovations has continued strengthening the financial foundation needed to support its clinical strategy.

The company recently announced an institutional funding arrangement representing a notional subscription amount of approximately CAD$5 million. The financing structure is intended to support key development priorities, including advancing ONC010 through manufacturing and preclinical activities, further development of the SynoGraph(TM) platform, and general corporate purposes.

For emerging biotechnology companies, securing capital ahead of major clinical milestones can be an important step in maintaining development timelines. The arrangement is structured to release proceeds across eighteen monthly tranches against a benchmark price, so the amount ultimately realized may be more or less than the notional subscription amount. By combining this financing structure with continued progress across manufacturing and IND-enabling activities, Onco-Innovations is working to establish the infrastructure needed to support its transition toward human trials.

Preparing for the Next Stage

Onco-Innovations has also strengthened its leadership team with the appointment of Dave Antony as Chief Financial Officer. Antony brings more than 35 years of experience spanning financial planning, reporting, corporate finance, governance and public company advisory matters.

With manufacturing advancements, regulatory preparation, strategic partnerships and a financing structure in place, Onco-Innovations is continuing to build the foundation required for the next stage of ONC010 development, which includes the continuation of its IND-enabling studies in support of a planned Phase 1 program in Australia.

For more information, visit https://oncoinnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at ibn.fm/ONNVF

• The current geopolitical disruption has exposed what energy analysts have long documented: The United States, despite being one of the world’s largest oil producers, still imports approximately 6.3 million barrels of crude oil per day.
• Frontieras is building a processing infrastructure to convert coal, a resource abundant in the United States, into the fuels and materials that American industry and transportation actually need.
• Frontieras is advancing its proprietary model from concept to construction.

Recent world geopolitical events have made one argument impossible to dismiss: Energy systems built around imported feedstocks and foreign supply chains carry risks that domestic production does not. Frontieras North America is working to strengthen its position in that domestic alternative, creating a production system that converts American coal into six essential byproducts, all within U.S. infrastructure and using a feedstock that never crosses a border or passes through a maritime chokepoint.

The scale of the current disruption is significant. When the United States and Israel launched strikes on Iran in late February 2026, Iran responded by effectively closing the Strait of Hormuz, the world’s most critical oil shipping passage. Reports confirmed the strait was functionally closed to commercial traffic, with insurance unavailable and crews unwilling to make the transit, describing it as potentially the greatest global energy supply shock in decades. Brent crude prices surged past $115 per barrel in early March, a 24% single-session increase, as the strait closure removed an estimated 15 million barrels of daily supply from global markets.

The disruption exposed what energy analysts have long documented: The United States, despite being one of the world’s largest oil producers, still imports approximately 6.3 million barrels of crude oil per day. The reason is structural. American refineries, particularly along the Gulf Coast, are configured to process heavy, sour crude — the kind produced in the Middle East and Venezuela — rather than the light, sweet crude that domestic shale fields produce in abundance. That mismatch means U.S. fuel production remains tethered to global crude markets and the shipping routes that connect them, even as domestic production hits record levels.

The Congressional Research Service noted that congressional concern had risen sharply following the February–March 2026 conflict, with oversight hearings focused on what a prolonged strait closure would mean for U.S. oil, gas and commodity prices. The answer, as markets demonstrated, is that it means severe and rapid price spikes across fuels, fertilizers and industrial inputs, a chain of disruption that reaches every sector of the American economy.

Coal does not travel through the Strait of Hormuz. It does not pass through any foreign port or foreign supply chain. The United States holds approximately 468 billion short tons in demonstrated coal reserves, a domestic resource base larger than remaining U.S. oil and gas reserves combined when measured by energy content. Annual production runs at roughly 500 million short tons. That resource sits entirely within U.S. territory, priced in domestic markets, and accessible without import logistics of any kind.

Frontieras is building the processing infrastructure to convert that resource into the fuels and materials that American industry and transportation actually need. Its FASForm(TM) process applies continuous thermal cracking and distillation to coal without combustion, separating it into six commercial products: ultra-low sulfur diesel, naphtha, jet fuel, FASCarbon(TM), ammonium sulfate fertilizer and sulfuric acid. No foreign feedstock enters the process. No overseas facility touches the output.

The coal feedstock behind FASForm also carries a structural pricing advantage. According to the IEA’s Coal 2025 analysis, “coal markets have shown more predictable and subdued price movements” compared to natural gas and crude oil, which “continue to be influenced by geopolitical risks and supply-side uncertainties.” The EIA similarly notes that coal contract prices tend to be more stable than those of other energy commodities. That means a coal-to-fuels system anchored to domestic inputs improves its margins in precisely the conditions, including geopolitical disruption and supply chain stress, that drive oil prices higher.

Frontieras is advancing its proprietary model from concept to construction. Its flagship Mason County, West Virginia facility, announced with an $850 million investment commitment and the backing of West Virginia Governor Patrick Morrisey, will process 7,500 tons of coal per day when operational. It will be powered predominantly by the hydrogen its own process generates, making it one of the first large-scale industrial plants in the United States to run on its own hydrogen output.

The energy disruptions of 2026 have compressed what was once a long-term policy debate into an immediate operational question: Where does American fuel come from when the global supply chain breaks down? Frontieras is building an answer to that question: a domestic production system that draws on the country’s most abundant energy resource and delivers the fuels and industrial materials that the economy runs on, without a single foreign input in the chain.

For more information about Frontieras, visit the company’s website at www.Frontieras.com.

NOTE TO INVESTORS: The latest news and updates relating to Frontieras are available in the company’s newsroom at https://ibn.fm/Frontieras

Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) and may include paid advertising.

Lafleur Minerals: Fully permitted Beacon Gold Mill and tailings pond, nearby Swanson Gold Deposit, make Lafleur a near-term gold producer in the Abitibi Gold Belt, ValDor, Canada.

The Val-d’Or mining camp sits in the heart of the prolific Abitibi Greenstone Belt, one of the richest gold-producing regions in the world.

Abitibi Gold Belt junior miner LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) is about to move from Beacon Gold Mill recommissioning stage to gold production at its fully permitted and refurbished Beacon Gold Mill, drawing on mineralized material that sits on site from last operations in 2022.

LaFleur Minerals’ Swanson Gold deposit which sits nearby covers 490 claims across approximately 23,101 hectares, and the company’s independent NI 43-101 technical report on March 27 incorporates recent confirmation drilling to demonstrate the potential for a scalable, capital-efficient restart of gold production.

Holding mining claims in Canada’s Abitibi Greenbelt, the largest gold-producing region in the country, is a promising start for a junior miner, but near-term gold producer LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) has moved well beyond that point, amassing key assets and putting a clear strategy in play as it prepares to start gold production later this year.

LaFleur is progressing through a refurbishing project that will leave its Beacon Gold Mill in position to process stockpiled material on site and from the nearby Swanson Gold Deposit at a rate of 750 tonnes per day (“TPD”), before increasing output by the end of the first year of operation to a 1,250 TPD target.

Key Takeaways

• The Beacon Gold Mill was operational only just a couple of years ago, when it was shuttered by a bankrupt former owner; planned refurbishing upgrades were 94% complete as of the company’s last statement on the work July 1
• When the upgrades are finished later this year, LaFleur will be able to start production immediately — drawing on an existing 10,000 to 20,000 metric tons of feedstock from the company’s Swanson Gold Deposit
• LaFleur is in discussions to raise up to C$30 million in a prepayment financing facility that is accompanied by a gold doré off-take agreement with Trafigura Canada Limited, the world’s largest private metal trader. The transaction is in late due diligence stage
• LaFleur has completed and filed its independent Preliminary Economic Assessment (“PEA”) that includes an all-in sustaining cost of just under $1,600 an ounce and a base case of $2,750/ounce gold price during a season when fluctuating spot gold prices have maintained levels well over $4,000 even amid a period of correction, touching $5,500 in January

490 Claims and Counting

Swanson Gold Deposit/Mckenzie Mineral Claims- Abitibi Gold Belt

LaFleur has expanded its acquisitions within the Abitibi Gold Belt during the past year from approximately 18,304 hectares (45,230 acres) in its original Swanson Gold Project to add 46 mineral claims across 1,781.18 hectares in the McKenzie East Gold Project and 27 mineral claims covering approximately 701.7 hectares in the Val-d’Or-Senneterre corridor. 

“Consolidating prospective, historically explored ground in the heart of the Abitibi Gold Belt in the same belt as our Swanson Gold Project and Beacon Gold Mill is central to our district-scale strategy,” LaFleur’s President of Exploration Marc Ducharme stated in June (https://ibn.fm/aDr0l).

Upgrading the Mineral Resource Estimate (“MRE”)

As LaFleur has continued to update its Mineral Resource Estimate, it has arrived at a current indicated resource of 2.96 million tonnes at an average grade of 1.69 g/t Au, containing 160,300 ounces of gold, and an inferred resource estimate of 1.08 million tonnes at an average grade of 1.93 g/t Au, containing 66,800 ounces of gold (https://ibn.fm/5yCBh).

Updated cut-off grades (“COG”) of 0.5 g/t Au using an open pit shell and 1.85 g/t Au using underground MSO shapes led to the 30% increase in indicated MRE ounces over the 2024 report, and an estimated seven-year life for the flagship Swanson Gold Deposit.

Recent drilling results have returned assays:

DRILLING HIGHLIGHTS

• 2.29 g/t Au over 68.30 metres (SW-25-079)
• 1.18 g/t Au over 255.04 metres (SW-25-080)
• 1.65 g/t Au over 136.1 metres (SW-25-081)

Location, Location, Location

Having near-term production at a gold mill, a tailing pond and a gold deposit all connected to the Val d’Or mining camp that supplies the region’s exploration needs demonstrate a clear strategic value. LaFleur has easy access to skilled labor and material resources, and a developed transportation network for moving material and resources around. 

That transportation network includes a rail line crossing LaFleur’s Swanson property that can help move material. LaFleur has been in talks with rail officials about a proposed spur from the main Canadian National (“CN”) line that would enable a direct mine-to-mill connection, facilitating even more economical transit between the sites. A direct connection would reduce over-the-highway traffic exposure and enhance overall environmental performance. 

Completion of a rail spur to the mill would also increase LaFleur’s ability to accept feed material from other satellite sources via the CN line, enhancing the potential of expanding its revenue sources.

For more information, visit the company’s website at LaFleurMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to LFLRF are available in the company’s newsroom at https://ibn.fm/LFLRF

Qualified Person Statement:

All scientific and technical information contained in this article has been reviewed and approved by Louis Martin, P.Geo. (OGQ), Exploration Manager and Technical Advisor of the company and considered a Qualified Person for the purposes of NI 43-101.

The 2026 Disruptive Growth & Life Sciences Conference takes place September 9–10 at The Westin New York Grand Central. There are years when a small-cap investor conference is a nice-to-have. This is not one of them. Two of the sectors that have moved most sharply in 2026, life sciences and the energy and compute infrastructure being built to support artificial intelligence, are both seeing significant activity at the small- and mid-cap end of the market. They are also sectors where understanding individual companies often requires more than reading filings and watching stock charts.

That makes the timing of the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference particularly interesting. The event brings both sectors together across two tracks and two days, giving investors access to companies operating in two areas that have helped shape the market this year.

Life sciences: the recovery arrived, but not everywhere. After three difficult years, biotech has turned a corner. The SPDR S&P Biotech ETF (XBI), a widely used proxy for small- and mid-cap biotech rather than the large pharmaceutical companies, posted a total return of roughly 80% over the twelve months ending in late August 2026. That is a meaningful change in sentiment for a sector that spent years under pressure.

There are fundamentals behind the move as well. The FDA’s Center for Drug Evaluation and Research had approved 36 novel drugs by August 28, 2026, a pace that puts the year alongside some of the agency’s more productive recent periods.

Dealmaking has been even stronger. CNBC reported biotech M&A at roughly $106 billion by early June, the best pace since before the pandemic, while BioPharma Dive counted 38 acquisitions completed by mid-year, the fastest run in seven years. With large pharmaceutical companies facing major patent expirations, many have been looking outside their own pipelines for new assets. That puts smaller biotech companies in an interesting position.

Richard H. Kreger, Moody Capital Solutions’ chairman and CEO, described the environment in the conference announcement as “unprecedented growth amid a spike of FDA approvals, corporate buyouts and deregulation.” The numbers help explain the optimism, but they also show that the recovery has not been evenly distributed.

Roughly 68 biotech companies raised more than $9.1 billion in venture capital during the first half of 2026, the strongest first half since 2022. About 76% of that capital, however, came through megarounds of more than $100 million, and roughly two-thirds of the rounds went to companies already conducting human trials.

The IPO market has followed a similar pattern. Thirteen biotech companies went public, raising a combined $4.5 billion at a median of approximately $302 million each.

For small-cap investors, that concentration matters. Capital is available, but much of it is going to a relatively narrow group of later-stage, more de-risked companies. Earlier-stage and lesser-known companies are still competing for attention and funding.

That is also where an in-person conference can be useful. Investors get the opportunity to hear directly from management teams, ask questions and compare companies that may receive little or no traditional research coverage.

AI’s infrastructure buildout is becoming its own investment story. The technology side of the conference is less about the companies making AI models and more about the infrastructure required to support them.

Morgan Stanley’s 2026 power outlook estimates that global electricity demand is increasing by more than one trillion kilowatt-hours annually through 2030, with AI-driven data centers accounting for nearly one-fifth of that growth.

Data center power requirements are projected to increase by roughly 126 gigawatts annually through 2028, an amount comparable to Canada’s entire annual electricity demand. In the United States alone, data center demand is forecast to reach 74 GW by 2028, against a projected shortfall of approximately 49 GW in available power.

For investors, the power gap is becoming an increasingly important part of the AI story.

Hyperscalers are expected to commit more than $1 trillion in capital expenditures across 2025 and 2026, while developers are already anticipating significant power constraints in 2027 and 2028. Morgan Stanley estimates that the resulting spread expansion could create roughly $350 billion in value across areas including natural gas, nuclear power, batteries and storage, microgrids and fuel cells. 

Much of that opportunity sits outside the handful of companies that dominate AI headlines. It includes suppliers, developers and component manufacturers throughout the infrastructure chain, many of which are smaller companies with limited analyst coverage.

Kreger noted that “artificial intelligence has lit a fire for quickly scaling emerging growth companies,” and the conference’s technology and energy roster reflects that view. Presenting companies span data center development, battery storage, wave and ocean power, lithium, semiconductors and cybersecurity.

So why put these two sectors together?

At first glance, life sciences and disruptive technology may seem like an unusual pairing for one conference. From an investment perspective, however, they share some important characteristics.

Both require significant amounts of capital. Both can move dramatically around individual catalysts. And in both sectors, smaller companies often operate well outside the coverage universe of major Wall Street research firms.

They are also benefiting from unusually active investment environments in 2026.

Biotech has seen a resurgence in acquisitions, funding and public-market activity. AI infrastructure is attracting enormous amounts of capital as companies race to secure the power, data centers and technology needed to support growing demand.

The benefits of those trends have not reached every company equally. For investors willing to look further down the market-cap spectrum, that creates both opportunity and risk, and makes direct access to management particularly valuable.

That is where a two-day, two-track conference can serve a practical purpose.

More than 50 companies are expected to participate, many of them under-covered, giving investors the chance to hear their stories directly and evaluate them against a market backdrop that has become considerably more favorable for both sectors.

The case for showing up in September is fairly straightforward: buyers are active, capital is available, and some of the companies that could benefit from those trends are still operating well outside the market’s spotlight.

To register for the Moody Capital 2026 Disruptive Growth and Life Sciences Conference, visit: https://moodycapital.com/conference/

• MindWave Innovations is sharpening its focus around a blockchain ecosystem built on MindChain, NILA, MindWaveDAO and a growing network of specialized Subnets.
• At the center of the strategy is MindChain, an Ethereum-compatible Layer 2 designed to provide the underlying infrastructure for the company’s broader ecosystem.
• Together, MindChain, NILA and MindWaveDAO form an interconnected framework through which MindWave aims to support scalable blockchain activity and specialized use cases.

Rather than pursuing a broad collection of digital-asset initiatives, MindWave Innovations Inc. (NYSE American: APUS) is concentrating its efforts around a defined blockchain ecosystem. The company’s current strategy centers on four interconnected components: MindChain, its native NILA token, MindWaveDAO and a Subnet architecture designed to support specialized blockchain environments.

That structure puts MindChain at the foundation of the company’s strategy. MindWave is developing the network as an Ethereum-compatible Layer 2, creating the underlying infrastructure on which the rest of the ecosystem can operate. NILA is intended to function as the network’s native asset, while MindWaveDAO provides a decentralized organizational and community layer and Subnets can enable more specialized blockchain environments.

This creates a connection between the blockchain and its underlying community. Rather than functioning as a standalone digital asset, NILA is being positioned as an integral component of the infrastructure MindWave is building around MindChain.

Supporting that ecosystem is MindWaveDAO, which serves as the decentralized organizational and community layer around the platform. The DAO is intended to support participation across the broader MindWave ecosystem while providing a framework through which users and stakeholders can engage with the network.

MindChain’s Subnet architecture adds another layer to the strategy by creating specialized environments for different applications. Examples include ALCI, which uses AI-driven analytics, blockchain verification and ecosystem data to tokenize environmental services into traceable financial assets; Nexus Global Partners, which focuses on tokenizing and managing institutional real estate assets through blockchain-enabled infrastructure; and BlockAssure, which is developing blockchain-powered insurance infrastructure across life annuity and non-life insurance. Together, these initiatives illustrate how MindChain’s architecture could support distinct use cases while remaining connected to a broader blockchain ecosystem.

Together, they form the foundation of MindWave’s effort to develop an integrated digital-asset ecosystem with infrastructure that can support different participants and applications.

For MindWave, the opportunity lies in developing this infrastructure as blockchain adoption continues to mature. The company is moving its focus toward the underlying network, token and ecosystem needed to support participation in a more scalable and specialized digital economy.

As MindChain progresses toward its planned mainnet launch, the development of NILA, MindWaveDAO and the Subnet architecture will be key components to watch as MindWave works to establish its blockchain ecosystem and position itself within the broader evolution of institutional digital-asset infrastructure.

For more information, visit the company’s website at www.MindWaveDAO.com.

NOTE TO INVESTORS: The latest news and updates relating to APUS are available in the company’s newsroom at https://ibn.fm/APUS

• SS Innovations is scaling its SSi Mantra surgical robotic system from an established Indian base into international markets.
• Second-quarter revenue rose 39.4% year over year to $13.9 million, while 30 SSi Mantra systems were installed during the quarter.
• The company entered the second half of 2026 with 224 systems installed across 12 countries and more than 12,000 cumulative procedures.
• Potential regulatory clearance in the United States and CE marking in Europe could materially enlarge SSII’s addressable market.
• The investment case is seen as attractive because SSII is still early in its commercialization curve, although investors must weigh cash consumption, regulatory risk, and potential dilution against its growth prospects.

SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, presents an attractive proposition for investors in the medical-technology sector. The company’s SSi Mantra system is being deployed at an increasing number of hospitals, surgeons are performing thousands of procedures with the platform, and SSII is beginning to establish an installed base outside its home market.

The latest quarterly figures show a company rapidly expanding from a relatively small original base. SSII reported second-quarter revenue of $13.9 million, an increase of 39.4% from the same period a year earlier. It installed 30 SSi Mantra systems during the quarter, compared with 23 in Q2 2025. First-half revenue reached $25 million, up 65.6% year over year.

As of June 30, the cumulative installed base had reached 224 systems across 12 countries. Hospitals using the platform had performed 12,272 procedures, including 637 cardiac operations, 222 pediatric procedures and 175 telesurgeries.

Those numbers provide important context for a recent Seeking Alpha analysis by Eborose Capital, which argues that SSII offers investors a potentially more asymmetric opportunity than the much larger Intuitive Surgical (NASDAQ: ISRG) (https://ibn.fm/Y2kq3).

The comparison is useful, but the more important point is what it says about SSII itself. Intuitive Surgical has an enormous installed base and a mature recurring-revenue model built around its da Vinci platform. SS Innovations is at an earlier stage. Its installed base is much smaller, but that also means there is considerably more room for expansion if the company can continue converting hospitals and surgeons to its technology.

The growth differential is already visible. SSII’s installed base increased from 105 systems at the end of Q2 2025 to 224 one year later, while quarterly procedures climbed from 1,042 to 2,528. System sales generated $12.4 million of Q2 revenue, up 40.8% year over year.

For an emerging medical-device company, utilization is particularly important. Selling a robot creates the installed base; procedures performed on that robot create opportunities for recurring instrument and service revenue. That is one reason SSII’s longer-term economics could look different from today’s revenue mix.

It would be a mistake, however, to characterize SS Innovations simply as a lower-cost alternative to Intuitive Surgical. Price is part of the company’s strategy, particularly in India and other healthcare markets where the capital cost of robotic surgery can limit adoption. But the more significant investment argument is whether SSi Mantra provides the capabilities hospitals and surgeons actually require.

The company’s current SSi Mantra 3 platform incorporates an open-face surgeon console with a large 3D 4K monitor, ergonomic hand controls and head-tracking technology. Its patient-side carts are modular, while the vision cart incorporates 3D 4K imaging and other operating-room equipment.

SS Innovations also supports multiple specialties, including urology, gynecology, general surgery, thoracic surgery and cardiac surgery. The company says the system is designed to give surgeons flexibility in configuring the robotic arms according to the procedure. That breadth is important because the economic value of a surgical robot ultimately depends on utilization. As an example of its growing utilization, a medical team in India utilized the SSi Mantra surgical robotic systems to successfully complete fifty gastric bypass procedures in a single day, demonstrating the robustness of the company’s technology.

India is particularly significant to the SSII story. The country has a huge population and a healthcare system in which access to advanced medical technology varies considerably between institutions and regions. SS Innovations has built its commercial operation in that environment rather than waiting for entry into the world’s largest developed healthcare markets. That has allowed the company to establish clinical experience while expanding its installed base.

The company’s own development history also provides a degree of credibility. Founder, Chairman and CEO Dr. Sudhir Srivastava is a robotic cardiac surgeon, and the company’s technology has been developed with applications in cardiac surgery alongside other specialties. SS Innovations also operates a training infrastructure intended to help surgeons transition to robotic procedures.

Telesurgery adds another dimension. In July, surgeons used SSi Mantra to conduct a robotic sleeve gastrectomy between Colombia and India across more than 13,600 miles of fiber-network distance, according to the company’s SEC filing.

The biggest potential change to SSII’s growth profile could come from outside India. The company is pursuing U.S. FDA 510(k) clearance and European CE marking for SSi Mantra. Those approvals would give SSII access to markets where robotic surgery is already well established and where hospitals have demonstrated willingness to invest in robotic-assisted procedures.

Importantly, much of SSII’s current growth has been achieved without access to the U.S. market. If the company eventually receives the necessary regulatory clearances, the potential market expands substantially beyond the countries in which it currently operates.

For more information, visit the company’s website at www.SSInnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII

• Nightfood Holdings, through TechForce Robotics, is expanding from hospitality robotics into AI, automation, and advanced manufacturing.
• The company combines proprietary technology, recurring Robotics-as-a-Service Provider deployments, and strategic acquisitions to create multiple avenues for growth.
• Through its Robotic Connective Network and proposed JJ Enterprise acquisition, NGTF is targeting commercial, industrial, and enterprise automation markets.

Nightfood Holdings (OTCQB: NGTF), doing business as TechForce Robotics, is building toward a broader role in the rapidly evolving automation and robotics economy. What began with a focus on hospitality automation is developing into a more diversified strategy spanning proprietary software, autonomous robotics, enterprise coordination, and advanced manufacturing.

For investors, the appeal of that strategy lies in its multiple layers. TechForce is not simply pursuing revenue from individual robot deployments. The company is developing an ecosystem that combines specialized machines with the software and infrastructure needed to coordinate them, while expanding into higher-value industrial and manufacturing markets.

One of the most significant developments in that evolution is TechForce’s proprietary Robotic Connective Network(TM). Launched in July 2026, the technology framework is designed to enable AI systems, robots, sensors, smart devices, and operational software to communicate and coordinate workflows across connected environments.

At its core is patent-pending decentralized task coordination technology designed to allow connected devices to negotiate task ownership based on real-time factors such as workload, proximity, battery capacity, and operating conditions. The objective is to reduce dependence on continuous human direction while allowing robotic fleets to respond dynamically as circumstances change.

That addresses a growing challenge in enterprise robotics. As organizations deploy multiple specialized machines, the opportunity increasingly extends beyond what any individual robot can accomplish. The next challenge is coordinating those systems so they can work together efficiently. TechForce is positioning its connective technology as part of the infrastructure needed to support that transition.

The company is also pursuing a recurring Robotics-as-a-Service Provider (“RaaSP”) model. Depending on the deployment, TechForce may provide facility assessment, mapping, systems integration, maintenance, technical support, software updates, training, and ongoing optimization. The model is designed to reduce upfront barriers for customers while potentially creating recurring revenue and opportunities to deepen customer relationships over time.

Another major component of Nightfood’s growth strategy is its proposed acquisition of a controlling interest in Jiun Jiang Enterprise Co., Ltd. The Taiwan-based company brings capabilities spanning semiconductor automation, advanced packaging equipment, industrial robotics, logistics, and precision manufacturing. The transaction could significantly broaden Nightfood’s addressable markets beyond service robotics. The companies are also evaluating a potential manufacturing expansion of up to approximately 100,000 square feet across Taiwan and the United States, subject to negotiations, approvals, and other conditions.

Nightfood’s existing hospitality assets add another dimension to the strategy. Beyond their operating and balance-sheet value, the properties can provide real-world environments where TechForce technologies can be tested, validated, and demonstrated under commercial conditions.

Taken together, these initiatives give Nightfood exposure to several interconnected growth themes: AI-enhanced robotics, enterprise automation, recurring RaaSP revenue, multi-robot coordination, semiconductor automation, and advanced manufacturing.

The strategy is not without execution risk, particularly surrounding the proposed JJ Enterprise transaction and future expansion plans. However, if TechForce can successfully connect its robotics, software, RaaSP model, and manufacturing capabilities, Nightfood could evolve from a hospitality-focused robotics company into a more diversified participant in the broader automation economy.

For more information, visit the company’s website at TechForceRobotics.com.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at https://ibn.fm/NGTF

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising.

• Onco-Innovations has advanced ONC010 across API manufacturing, polymer optimization, analytical development, preclinical characterization and clinical planning as it works toward human evaluation.
• A 300-gram development batch of ONC010’s active ingredient achieved approximately 99.3% purity, while a newly identified non-tin catalyst could support improved control of impurities in future polymer manufacturing.
• The company is building an Australian pathway for a potential First-in-Human study while advancing bioanalytical, metabolism, ADME, toxicology, biodistribution and regulatory preparation during the second half of 2026.

Cancer therapies built around DNA damage face a fundamental biological obstacle: cancer cells can repair the very damage meant to destroy them. That has made DNA Damage Response (“DDR”) inhibition an important field in oncology, where the goal is to disable specific repair mechanisms and leave cancer cells more vulnerable to treatment.

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) is a preclinical-stage company pursuing an emerging target in that field, Polynucleotide Kinase Phosphatase, or PNKP. Its lead candidate, ONC010, pairs a small-molecule PNKP inhibitor with a nanoparticle delivery system. The company’s latest update brings together previously announced advances in API manufacturing, polymer development, analytical controls and preclinical characterization while adding a newly identified non-tin catalyst for the polymer synthesis process. Collectively, the work reflects a program increasingly focused on the manufacturing, preclinical and regulatory infrastructure required for clinical development.

Targeting Cancer’s Repair Machinery

PNKP is involved in the repair of damaged DNA strands. Onco’s strategy is to inhibit that repair process, potentially allowing DNA damage to accumulate in cancer cells.

The approach is designed to work in multiple ways. PNKP inhibition may enhance the effects of DNA-damaging treatments such as radiation and certain chemotherapies, while potentially creating synthetic lethality in cancers carrying specific genetic deficiencies. Onco identifies PTEN and SHP-1 deficiencies among potential synthetic lethal partners.

PARP inhibitors helped establish the broader DDR inhibitor field and are now used to treat several cancers. Onco’s presentation reports that DDR inhibitors generated more than $7 billion in sales during 2025 and positions PNKP as a distinct emerging class beyond PARP.

ONC010 adds nanoparticle delivery to the approach. It encapsulates A83B4C63, Onco’s exclusively licensed small-molecule PNKP inhibitor, inside PEO-b-PBCL, a micellar nanocarrier designed to influence circulation time, tumor accumulation and drug exposure. The delivery system, developed under an exclusive sublicense, represents an additional development challenge because the company must establish not only a reproducible API manufacturing process, but also consistent production of the polymer and resulting nanoparticle formulation.

Building a Reproducible Drug Product

Working with Dalton Pharma Services, Onco advanced ONC010’s active pharmaceutical ingredient from laboratory synthesis through intermediate production and completed a 300-gram development-scale batch of A83B4C63 at approximately 99.3% purity, with residual solvents below the detection limits of the analytical methods employed.

The company also completed an analytical reference-standard preparation program for A83B4C63. The highly characterized material is intended to support future assessment of API identity, purity, stability, impurity profiles and batch-to-batch comparability. Together, these activities are intended to strengthen the analytical controls surrounding future manufacturing, formulation work and clinical-material production.

Polymer manufacturing represents the other critical component of ONC010 because the drug candidate depends on its nanoparticle delivery system. Onco has advanced an analytical method using refractive index detection coupled with gel permeation chromatography to characterize the polymer’s molecular weight, molecular-weight distribution and polydispersity index.

Those characteristics can influence nanoparticle formation, particle-size consistency, drug loading and formulation reproducibility. In parallel, Nanosoft Polymers has been optimizing polymer synthesis, purification and scalability.

The latest development centers on Nanosoft’s identification of a non-tin catalyst for continued polymer-process development. The company expects the approach could support better control of catalyst-related impurities while contributing to a more consistent and reproducible polymer manufacturing process suitable for eventual GMP production. Nanosoft will continue evaluating the catalyst as development progresses.

Preparing for the Clinical Transition

Manufacturing advances are being paired with a growing preclinical program. Nucro-Technics is developing and executing specialized liquid chromatography-mass spectrometry methods to measure A83B4C63 in biological samples generated through Onco’s non-GLP pharmacokinetic and biodistribution animal study.

The resulting analytical capabilities are intended to help characterize compound exposure and distribution while supporting future dosing strategies and planning for subsequent GLP-compliant studies.

Onco has also initiated hepatocyte and liver microsome metabolism studies across human, rat and dog systems. These studies are designed to characterize intrinsic clearance, metabolic degradation and species-specific metabolism, information that can contribute to toxicology-study design, pharmacokinetic modeling, dose selection and regulatory planning.

In July, the company initiated additional absorption, distribution, metabolism and excretion (“ADME”) studies, initially focused on the metabolism of the API used in ONC010. Together, these studies are intended to build a more complete understanding of the candidate’s pharmacokinetic and metabolic profile as the program advances through its IND-enabling work.

That work builds on earlier animal research using nanoparticle formulation. Findings published in the Journal of Controlled Release in 2021 reported slower tumor growth and improved survival in PTEN-deficient models, favorable pharmacokinetics and low observed toxicity, along with sensitization to radiation and topoisomerase I inhibitors. Preclinical results do not establish safety or efficacy in humans, which is precisely why the current transition toward formal clinical development matters.

Australia Provides the Clinical Pathway

Onco has established Onco-Innovations AU Pty. Ltd. as a wholly owned Australian subsidiary and engaged Research & Development Incentives Partners (RDI Partners) to support its Australian operations. The company is also continuing to work with Avance Clinical toward potential Phase I development in Australia.

The Australian structure provides a local operating and governance framework for planned Phase I activities while the company works toward potential submission to a Human Research Ethics Committee and progression through Australia’s Therapeutic Goods Administration Clinical Trial Notification pathway.

The company has also strengthened its scientific and clinical leadership with the appointments of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development. The additions provide additional oversight across clinical strategy, research planning and coordination with external development partners.

“The ONC010 program is moving from a collection of individual development activities into an increasingly integrated CMC, preclinical and clinical-readiness program,” Mohamed said.

That integration is becoming increasingly important as Onco moves beyond individual laboratory milestones. API manufacturing, polymer development, analytical controls, pharmacokinetic and metabolism studies and clinical planning now need to advance in parallel and ultimately converge into a package capable of supporting human evaluation.

During the second half of 2026, Onco expects to continue manufacturing scale-up, analytical qualification, polymer optimization, toxicology and biodistribution studies, clinical protocol development and regulatory preparation supporting the Australian First-in-Human pathway.

The challenge now is turning years of science into a reproducible drug product supported by the manufacturing controls, preclinical evidence and regulatory documentation required to enter the clinic. If execution continues as planned, the next chapter for ONC010 will be measured less by individual laboratory milestones and more by the company’s ability to translate those pieces into a coordinated pathway toward evaluation in patients.

For more information, visit https://oncoinnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at ibn.fm/ONNVF